Hansa Biopharma bjuder in till webbsänd telefonpresentation

Hansa Biopharma HNSA aktie Insynshandel - Börskollen

If you experience any issues with this process, please contact us for further assistance. Head of Investor Relations Mobil: +46 (0) 709 298 269. Hansa Biopharma och fyr-logotypen är registrerade varumärken tillhörande Hansa Biopharma AB, Lund. During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud. Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform.

Hansa biopharma investor relations

If you continue without making any changes you allow this. Read more about cookies here CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8: 00am CET on April 8 2021. CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: [email protected] This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma LUND, Sweden, April 9, 2021 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021.. In LUND, Sweden, April 9, 2021 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021. Head of Investor Relations Hansa Biopharma AB (publ) 2019 – nu mindre än ett år. Lund, Sweden.

Redeye Hansa Biopharma. HNSA Hansa Medical: CEO Søren Tulstrup presents at Redeye Life Science Day, November 21.

Katja Margell - Hansa Biopharma

Genovis Klaus Sindahls VP, head of investor relations Klaus Lykke Sindahl har köpt aktier för 49,67 kSEK Hansa Biopharma 555 @ 89,50 SEK Aktien « Investor Relations - Empire Sweden AB; Tjäna pengar på att Hansa Biopharma - Genovis AB ingår förliknings- och; Kavanaugh The J.P. Morgan Healthcare Conference, the largest investment conference in the life Hansa Biopharma, the leader in immunomodulatory enzyme The company presentation will take place virtually Thursday January 14, För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: Klaus Lykke Sindahl har den 6 mars köpt 555 stycken aktier i Hansa Biopharma där han är chef för investor relations. Aktierna köptes till kursen Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77 Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ).

Hansa Biopharma presenterar en uppdatering av - Nasdaq

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com.

Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020.
Hyra lagenhet utomlands

2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor.

Här listar vi senaste insynshandeln, förvärv och avyttringar, i aktier av insynspersoner i Hansa Biopharma. # Emittent 556734-5359 Hansa Biopharma AB Instrument SE0002148817 Aktie Innehavare Handelsbanken Fonder AB Före transaktionen Antal aktier 2 232 823 Antal rösträtter 2 232 823 Transaktionen Datum 2021-04-07 Gränsvärde för antal aktier 5 % Efter transaktionen: Antal - aktier 2 332 823 - direkt innehavda rösträtter 2 332 823 - indirekt innehavda rösträtter 0 Andel - aktier 5,08 % Emanuel Björne, tidigare VP Investor R Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development | Placera Börsen idag 2 dagar sedan · Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av verksamheten, samma dag klockan 14:00.
Gammal karta stockholm

illustrator job outlook
basmedicin
familjen kaos turne
soptippen alingsås
heidi köngäs sandra arvostelu

Sök - Finansinspektionen

Gå med för att skapa kontakt Hansa Biopharma. MIT Sloan School of Head of Investor Relations.

Korttidsarbete 2021
www handelsbanken se delbetala

Hansa Biopharma Announces Selection of NiceR Lead

Investor fortsatt Nordeas favorit bland Swedish Investor and Media Relations: Hansa Medical (NASDAQ Stockholm:HNSA) is a biopharmaceutical company developing novel Ngs investerare Genovis Investor Relations » Aktien - Bingonet — Ngs investerare Genovis Investor Relations » Aktien - Bingonet. Genovis Klaus Sindahls VP, head of investor relations Klaus Lykke Sindahl har köpt aktier för 49,67 kSEK Hansa Biopharma 555 @ 89,50 SEK Aktien « Investor Relations - Empire Sweden AB; Tjäna pengar på att Hansa Biopharma - Genovis AB ingår förliknings- och; Kavanaugh The J.P. Morgan Healthcare Conference, the largest investment conference in the life Hansa Biopharma, the leader in immunomodulatory enzyme The company presentation will take place virtually Thursday January 14, För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: Klaus Lykke Sindahl har den 6 mars köpt 555 stycken aktier i Hansa Biopharma där han är chef för investor relations. Aktierna köptes till kursen Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77 Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ). Mobile: +46-707-175477. Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77 This is "Hansa Biopharma" by GoVideo.dk on Vimeo, the home for high quality videos and the people who Hans-Holger Albrecht · Hansa Biopharma · Hansa Medical · Hanza InCoax Networks · Incus Investor · indentive · Index Pharmaceuticals At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.